Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non Operating Income (2018 - 2025)

Zevra Therapeutics' Other Non Operating Income history spans 6 years, with the latest figure at -$265.9 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 3630.87% year-over-year to -$265.9 million; the TTM value through Dec 2025 reached -$140.5 million, down 13358.33%, while the annual FY2025 figure was -$133.7 million, 2254.24% down from the prior year.
  • Other Non Operating Income reached -$265.9 million in Q4 2025 per ZVRA's latest filing, down from -$6.6 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $135.4 million in Q2 2025 to a low of -$265.9 million in Q4 2025.
  • Average Other Non Operating Income over 3 years is -$15.8 million, with a median of -$3.5 million recorded in 2024.
  • The largest YoY upside for Other Non Operating Income was 7470.08% in 2025 against a maximum downside of 3630.87% in 2025.
  • A 3-year view of Other Non Operating Income shows it stood at $789000.0 in 2021, then surged by 854.5% to $7.5 million in 2024, then crashed by 3630.87% to -$265.9 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Other Non Operating Income are -$265.9 million (Q4 2025), -$6.6 million (Q3 2025), and $135.4 million (Q2 2025).